Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Am J Transplant. 2017 Jul 11;17(9):2285–2299. doi: 10.1111/ajt.14349

Figure 1. Kidney Transplant Treatment Schema.

Figure 1

All animals received methylprednisolone (subcutaneous injection according to the following schedule, d0: 20 mg, d1: 16 mg, d2: 12 mg, d3: 8 mg, d4: 4 mg, d5–14: 3mg, d15–140: 1mg) and mycophenalate mofetil (30mg/kg bid, d0-d140) to recapitulate clinically relevant immunosuppression strategy. A subset (n=8/16) of belatacept treated animals received basiliximab induction therapy (0.3mg/kg d0, d4). All Tacrolimus treated animals received basiliximab induction. Belatacept therapy was discontinued at day 140 (d0: 10 mg/kg, d4: 15 mg/kg, d14-d56: 20 mg/kg bi-weekly, d56-d140: 20 mg/kg every 4 weeks). Tacrolimus trough levels were monitored weekly (8–12ng/ml d0–56, 5–8ng/ml d57–168, Supplemental Figure 4).